Study on the reversal effect of Qingfei huayu jiedu formula on drug resistance in non-small cell lung cancer cells
- VernacularTitle:清肺化瘀解毒方对非小细胞肺癌细胞耐药的逆转作用研究
- Author:
Shuailong CHEN
1
;
Huihui LIU
1
;
Feng SANG
2
;
Lifeng JIANG
3
Author Information
1. Dept. of Hematology and Oncology，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450003，China;Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine，Henan Province，Zhengzhou 450003，China
2. AIDS Clinical Research Center，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450003，China
3. Dept. of Integrated Traditional Chinese and Western Medicine，Henan Cancer Hospital，Zhengzhou 450008，China
- Publication Type:Journal Article
- Keywords:
Qingfei huayu jiedu formula;
non-small cell lung cancer;
gefitinib resistance;
miR-641/ERK signaling pathway
- From:
China Pharmacy
2026;37(12):1553-1558
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the reversal effect of Qingfei huayu jiedu formula （QFHYJDF） on drug resistance in non-small cell lung cancer （NSCLC） cells based on the microRNA-641 （miR-641）/extracellular signal-regulated kinase （ERK） signaling pathway. METHODS The human parental NSCLC cell line A549 was used to establish gefitinib-resistant cells A549/GR by combining concentration gradient increment with high-concentration pulse strategy. After screening for optimal intervention concentration and duration， the resistant cells were divided into a control serum group （treated with 20% blank serum for 48 h）， QFHYJDF-containing serum group （treated with 20% QFHYJDF-containing serum for 48 h）， and the normally cultured group （normally cultured for 48 h）. The cell relative viability， total apoptosis rate， as well as the expression levels of miR-641， neurofibromin 1 （NF1）， ERK1/2， and phosphorylated ERK1/2 （p-ERK1/2）， were assessed in each group. RESULTS Compared with the normally cultured group and the control serum group， the QFHYJDF-containing serum group exhibited significantly decreased cell relative viability and significantly increased total apoptosis rate （ P ＜0.05）. Moreover， the expression of NF1 protein was significantly up-regulated， while the expression levels of miR-641 and p-ERK1， p-ERK2 proteins were significantly down-regulated in the QFHYJDF-containing serum group （ P ＜0.05）. CONCLUSIONS QFHYJDF can inhibit proliferation and promote apoptosis of gefitinib-resistant lung cancer cells， which may be associated with up-regulating NF1 protein expression， down-regulating miR-641 expression， and inhibiting the activity of the ERK signaling pathway.
